Quantcast
Last updated on April 16, 2014 at 12:11 EDT

Latest Lamivudine Stories

2013-12-18 12:25:41

MUMBAI and BALTIMORE, December 18, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary Lupin Pharmaceuticals Inc. has launched its Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg / 300 mg in the US after the US District Court for the District of Delaware ruled that the Lupin's generic version of Trizivir(R) did not infringe on patents. Lupin had earlier received approval for the same. Lupin's...

2013-10-22 12:29:36

LONDON, Oct. 22, 2013 /PRNewswire/ -- ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lamivudine for the treatment of people living with HIV-1. This New Drug Application (NDA) follows the approval of dolutegravir by the US Food and Drug Administration (FDA) in August 2013 under the brand name Tivicay(®), approved for use in combination with other...

2013-07-01 15:03:01

Immediate, expanded, and improved treatments needed for infants and toddlers with HIV The World Health Organization's new HIV treatment guidelines, released today at the 2013 International AIDS Society (IAS) Conference, include new antiretroviral (ARV) therapy (ART) recommendations for HIV-infected children, and will mean that more children will be on better treatments. The Drugs for Neglected Diseases initiative (DNDi) applauds the new guidelines and, with Cipla Ltd. and other partners,...

2013-05-21 16:27:50

MILLBROOK, N.Y., May 21, 2013 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc., is pleased to announce the appointment of Arshad Siddiqui, Ph.D. to its Board of Directors. Dr. Siddiqui received a Ph.D. in chemistry from the University of Waterloo, Ontario, Canada. He was an associate director of antiviral chemistry at Shire BioChem Pharma where he was responsible for the development of several clinical candidates in the area of HIV, HBV and HCV. Dr. Siddiqui relocated to...

2012-08-02 06:24:36

PITTSBURGH and HYDERABAD, India, Aug. 2, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the establishment of a new agreement between its subsidiary Mylan Laboratories Limited and Gilead Sciences Inc. Under this agreement, Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies containing Emtricitabine, including single and fixed-dose combinations. Emtricitabine is marketed by Gilead under the brand name Emtriva(®), and a fixed-dose...

2012-07-26 10:27:38

WASHINGTON, July 26, 2012 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today announced 48-week data from the SPRING-2 Phase III study, which is evaluating the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1 infection. In this double-blind, double-dummy study, the proportion of study participants who were virologically suppressed (HIV-1 RNA <50 c/mL) was 88% for once-daily dolutegravir (DTG) and 85% for twice-daily raltegravir (RAL), with a 95%...

2012-07-10 22:20:59

LONDON, July 11, 2012 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1. The study demonstrated superiority of the dolutegravir-based regimen compared to the single tablet regimen Atripla®. At 48 weeks, 88% of study participants on the dolutegravir regimen were virologically suppressed (<50...

2012-06-22 06:15:16

(Ivanhoe Newswire) -- About 0.2% of pregnant women are HIV positive and 1/3 will pass the virus to their baby before it is born if no treatment is given. A new study breaches the safety and efficacy of adding antiretroviral drugs (HIV treatment drugs) to standard zidovudine prophylaxis (standard HIV prevention drugs) in infants of mothers with HIV who did not receive antenatal antiretroviral therapy because of late identification. Within 48 hours after their birth, researchers randomly...

2012-06-21 17:29:44

Non-breastfed babies born to HIV-positive mothers who didn't receive antiretroviral therapy during pregnancy are routinely given zidovudine, commonly known as AZT, shortly after birth to prevent mother-to-child transmission of the virus that causes AIDS. While effective, this strategy doesn't always protect the infant from acquiring the virus during the mother's labor and delivery. But a new UCLA-led study published June 21 in the New England Journal of Medicine finds that a two- or...

2012-06-21 11:14:16

Findings from NIH network support shift in prevention guidelines Adding the drug nevirapine to the regimen given to newborns of women diagnosed with HIV shortly before or during labor halves the newborns' risk of contracting the virus, according to findings by a National Institutes of Health research network. The researchers found that the rate of mother-to-child HIV transmission around the time of delivery was 2.2 percent among infants who received the standard drug zidovudine combined...